Perspectives on treatment of metastatic castration-resistant prostate cancer
Axel S Merseburger, Joaquim Bellmunt, Cheryl Jenkins, Chris Parker, John M Fitzpatrick, European Treatment Practices Group, Axel S Merseburger, Joaquim Bellmunt, Cheryl Jenkins, Chris Parker, John M Fitzpatrick, European Treatment Practices Group
Abstract
The arrival of several new agents--cabazitaxel, abiraterone acetate, enzalutamide, and radium-223--is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
Keywords: Abiraterone acetate; Cabazitaxel; Docetaxel; Enzalutamide; Metastatic castration-resistant; Prostate cancer; Treatment.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
Figures
Source: PubMed